Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enGene Holdings Inc. - Common Stock (NQ:ENGN)

9.110 +3.100 (+51.58%)
Streaming Delayed Price Updated: 1:20 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about enGene Holdings Inc. - Common Stock

< Previous 1 2 3 Next >
Let's take a look at the stocks that are in motion in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial
enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing. 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
ENGN Stock Soars On Hopeful Data From Bladder Cancer Study
The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026. 
Via Stocktwits
Get insights into the top gainers and losers of Tuesday's pre-market session.
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
From enGene Holdings Inc.
Via Business Wire
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
enGene Named a BioSpace 2026 Best Places to Work Winner
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles
enGene posts wider-than-expected Q3 loss as R&D spending doubles. The biotech advances its pivotal LEGEND trial and secures key FDA RMAT designation. 
Via Chartmill
enGene Posts 78% Expense Jump in Q3
Via The Motley Fool
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
From enGene Holdings Inc.
Via Business Wire
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
enGene Announces the Resignation of its Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
enGene to Present at the Jefferies Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
enGene Names Amy Pott as Chief Global Commercialization Officer
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.